I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: U.S. PATENT AND TRADEMARK OFFICE, BOX SEQUENCE, P.O. BOX 2327 ARLINGTON, VA 22202 ON THE DATE

INDICATED BELL

DATE: May.

PATENT **BOX SEQUENCE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

Haig H. Kazazian, Jr. et al.

: Group Art Unit: 1632

RECEIVED

Appln. No.:

09/653,812

: Examiner: A. Falk

NOV 0 8 2002

Filed:

September 1, 2000

: Attorney Docket

TECH CENTER 1600/2900

For:

COMPOSITIONS AND METHODS: No.: 053893-5006-02

OF USE OF MAMMALIAN

(9596-23U3)

RETROTRANSPOSONS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that (X) the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.. :
- I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) () does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages . I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.



(X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Applicants respectfully submit that an amendment to the specification of the above-captioned application, including a "marked-up" and "clean" copy of the Brief Description of the Drawings was filed with a Certificate of Mailing dated July 30, 2002. The amendment was submitted in accordance with MPEP §2422.02 in order to include sequence identifiers in the present sequence listing in the Brief Description of the Drawings. The CRF sequence listing submitted with the amendment of July 30, 2002 was damaged, and the present CRF copy of the sequence replaces the damaged copy. The amendment added no new matter as the sequences were already disclosed in the application as filed.

Respectfully submitted,

KAZAZIAN ET AL.

By:

KATHRYN DOYLE, PH.D., J.D.

Registration No. 36,317

MORGAN, LEWIS & BOCKIUS, L.L.P.

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: 215-963-5000 **Direct Dial: 215-963-4723** Facsimile: 215-963-5299

E-Mail: kdoyle@morganlewis.com

KD/JDGB

Enclosure: CRF sequence listing

November 4 2002 (Date)

Paper Copy of sequence listing Copy of Notice to Comply





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/653,812	9/1/00	Kazazian et al.		9596-23U3

EXAMINER				
Anne-Marie Bak	ter, Ph.D.			
ART UNIT	PAPER NUMBER			
1632	15			

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The disk submitted August 5, 2002 is damaged. Do not send disks to the 20231 zip code. See the attachments for specific mailing information.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENŢ of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Anne-Marie Falk, Ph.D. whose telephone number is (703) 306-9155. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Deborah Reynolds whose telephone number is (703) 305-4051. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Anne-Marie Falk, Ph.D.

Anne-Marie Dalk ANNE-MARIE BAKER PATENT EXAMINER DE

PATENT EXAMINER RECEIVED

NOV 0 8 2002

Application No.:09/653,812	Application No.:_		09/653,812
----------------------------	-------------------	--	------------

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
X	 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ap	plicant Must Provide:
X	An substitute computer readable form (CRF) copy of the "Sequence Listing".
	A substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	r questions regarding compliance to these requirements, please contact:
	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212
	tentin Software Program Support
	Technical Assistance703-287-0200
	To Purchase PatentIn Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY